New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir

Abstract: Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency virus. Fixed-dose combination rilpivirine-tenofovir-emtricitabine is a recently approved therapy option that has been extensively studied within the treatment-naive population. When compared with efavirenz-based therapy, improved tolerability with rilpivirine-based therapy was balanced by higher rates of virologic failure to provide similar overall efficacy rates within the intention-to-treat analysis. As a result, providers will need to balance the potential for improved tolerability with fixed-dose combination rilpivirine-tenofovir-emtricitabine against a higher potential for virologic failure, particularly among patients with baseline viral loads above 100,000 copies/mL. Current treatment guidelines have recommended that fixed-dose combination rilpivirine-tenofovir-emtricitabine be an alternative therapy option for treatment-naive patients and advise caution in those patients with high viral loads at baseline. Similar to other non-nucleoside reverse transcriptase inhibitor-based regimens, there are a number of drug interaction concerns with fixed-dose combination rilpivirine-tenofovir-emtricitabine that will necessitate monitoring and, in some cases, appropriate management. Additionally, the emergence of drug resistance to fixed-dose combination rilpivirine-tenofovir-emtricitabine has been well documented in clinical studies and close attention will be necessary in order to protect current and future therapy options. Overall, fixed-dose combination rilpivirine-tenofovir-emtricitabine is poised to provide an important therapy option for patients when appropriately applied.

Keywords: rilpivirine, human immunodeficiency virus, antiretroviral, tenofovir, emtricitabine

Introduction

Antiretroviral therapy has evolved over the past two decades into a highly efficacious, well tolerated, and conveniently dosed group of therapies. Clinical studies of treatment-naive patients demonstrate virologic suppression rates above 80% for many of the new treatment regimens. In order to meet and maintain these high virologic suppression rates, strict medication adherence is necessary. Combination products, particularly among the nucleoside reverse transcriptase inhibitor class of agents, have become a standard of care to reduce pill burden and potentially improve adherence. However, since antiretroviral therapy is composed of a minimum of three active agents, patients may still require the administration of multiple tablets, regardless of the availability of nucleoside reverse transcriptase inhibitor combination tablets. This has changed with the creation of single-tablet regimens. The fixed-dose combination of efavirenz-tenofovir-emtricitabine was the first available daily-dosed single tablet that provided a complete antiretroviral regimen. Since its approval, fixed-dose combination efavirenz-tenofovir-emtricitabine...
has become an attractive and highly prescribed therapy for treatment-naïve patients due to strong efficacy data, good tolerability, and its low pill burden.\(^6\)\(^,\)\(^7\)\(^,\)\(^10\)\(^,\)\(^11\) The development of additional single-tablet regimens continues to be sought as a result of concerns about toxicity, resistance, and teratogenicity risks with the efavirenz component of fixed-dose combination efavirenz-tenofovir-emtricitabine.\(^12\)\(^–\)\(^14\) Fixed-dose combination rilpivirine-tenofovir-emtricitabine represents a more recently approved single-tablet regimen.\(^15\) Similar to fixed-dose combination efavirenz-tenofovir-emtricitabine, fixed-dose combination rilpivirine-tenofovir-emtricitabine contains tenofovir and emtricitabine, while the efavirenz component is replaced by rilpivirine. To date, fixed-dose combination rilpivirine-tenofovir-emtricitabine has demonstrated strong efficacy data and good tolerability and is poised to provide a valuable therapy option for human immunodeficiency virus (HIV)-infected patients.\(^1\)\(^,\)\(^3\) This paper reviews the efficacy, pharmacokinetics, tolerability, drug interaction potential, and resistance concerns with fixed-dose combination rilpivirine-tenofovir-emtricitabine. Given that the rilpivirine component of this fixed-dose combination is most recently available, we discuss this agent in more detail in the context of a fixed-dose combination.

**Pharmacology**

Fixed-dose combination rilpivirine-tenofovir-emtricitabine is composed of three active antiretroviral agents, i.e., rilpivirine 25 mg (rilpivirine hydrochloride 27.5 mg), tenofovir disoproxil fumarate 300 mg (tenofovir disoproxil 245 mg), and emtricitabine 200 mg.\(^16\) Dosage and administration characteristics of this fixed-dose combination are shown in Table 1.\(^17\) Consistent with current therapy recommendations for treatment-naïve patients, this combination spans two major classes of antiretroviral agents.\(^6\)\(^,\)\(^7\) Rilpivirine is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI).\(^18\) Similar to other NNRTIs, rilpivirine inhibits viral DNA polymerization by binding to the hydrophobic pocket near the active site of reverse transcriptase.\(^19\) As a diarylpyrimidine NNRTI, rilpivirine is commonly referred to as a “next-generation” or “second-generation” NNRTI. Agents from this subclass possess a more flexible dihedral angle between the aniline ring and cyanovinyl moiety when compared with first-generation agents.\(^7\)\(^,\)\(^20\) This characteristic allows for binding to multiple modes within the highly flexible NNRTI binding site of reverse transcriptase and potentially leads to an improved resistance profile, although currently available clinical study data with rilpivirine have placed this advantage into question.\(^1\)\(^,\)\(^3\)

<table>
<thead>
<tr>
<th>Table 1 Administration and place in therapy(^{17,71})</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dosage and administration</strong></td>
</tr>
<tr>
<td><strong>Dosage form</strong></td>
</tr>
<tr>
<td><strong>Strengths</strong></td>
</tr>
<tr>
<td><strong>Dosage adjustments</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Important adverse effect</strong></td>
</tr>
<tr>
<td><strong>concerns that may require</strong></td>
</tr>
<tr>
<td><strong>monitoring</strong></td>
</tr>
<tr>
<td><strong>Recommended place in therapy</strong></td>
</tr>
<tr>
<td><strong>per antiretroviral treatment</strong></td>
</tr>
<tr>
<td><strong>guidelines</strong></td>
</tr>
<tr>
<td><strong>Alternative therapy option for</strong></td>
</tr>
<tr>
<td><strong>NNRTI-based antiretroviral therapy</strong></td>
</tr>
</tbody>
</table>

**Abbreviations:** NNRTI, non-nucleoside reverse transcriptase inhibitor; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.

Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor.\(^22\) Following absorption, this compound is converted to tenofovir by diester hydrolysis and then subsequently phosphorylated to form tenofovir diphosphate.\(^22\) The addition of a phosphate group is the key structural difference between a nucleoside and nucleotide, although clinically these drug classes are considered to be largely equivalent. Tenofovir diphosphate inhibits HIV reverse transcriptase by competing with the natural substrate deoxy-adenosine 5′-triphosphate for incorporation into viral DNA, leading to termination of viral DNA growth.\(^22\) Tenofovir is active against both HIV-1 and HIV-2 and also has activity against hepatitis B virus.\(^23\)\(^,\)\(^24\)

Emtricitabine is a nucleoside reverse transcriptase inhibitor.\(^25\) Emtricitabine is the (−)-enantiomer of a thio analog of cytidine and, unlike other cytidine analogs, has a fluorine in the 5-position.\(^26\) The molecular structure of emtricitabine is highly similar to another antiretroviral agent, lamivudine. In clinical practice, these agents are commonly considered to be interchangeable in terms of efficacy and safety.\(^6\)\(^,\)\(^7\)\(^,\)\(^27\) Emtricitabine also has activity against HIV-1, HIV-2, and hepatitis B virus.\(^25\)\(^,\)\(^28\)
Clinical pharmacokinetics
The pharmacokinetic characteristics of each of the components of fixed-dose combination rilpivirine-tenofovir-emtricitabine are presented in Table 2.21,22,29–32 The pharmacokinetics of each agent supports once-daily dosing. The plasma elimination half-lives are approximately as follows: rilpivirine 48 hours; tenofovir 17 hours; and emtricitabine 10 hours.22,29–31,33 The intracellular elimination half-lives of tenofovir and emtricitabine are significantly longer and approximated as follows: tenofovir 150 hours and emtricitabine 39 hours.31 As a result, this fixed-dose combination can be conveniently dosed on a once-daily basis.

When fixed-dose combination rilpivirine-tenofovir-emtricitabine was administered with food (400 kcal and 13 grams of fat) in healthy subjects, rilpivirine, tenofovir, and emtricitabine exposures were bioequivalent to the administration of the individual tablets. When the fixed-dose combination was administered to healthy subjects in the fasted state, rilpivirine and emtricitabine concentrations were approximately 25% higher when compared with administration of the individual tablets.16,34 As a result of these differences, it is recommended that fixed-dose combination rilpivirine-tenofovir-emtricitabine be administered with a meal.16 However, no specific meal type has been recommended. Rilpivirine should not be administered with a high protein meal, such as protein-rich nutritional drinks, because exposures are reduced by 50%.17,35 The solubility and subsequent systemic absorption of rilpivirine is pH-dependent, as demonstrated by a significantly increased bioavailability when given in an acidic environment. When coadministered with acid suppressants, significant reductions in drug absorption were observed.16 As a result, fixed-dose combination rilpivirine-tenofovir-emtricitabine should not be coadministered with proton pump inhibitors. H2 antagonists may be coadministered with this fixed-dose combination if spaced appropriately, as discussed in the drug interaction section.16

The components of fixed-dose combination rilpivirine-tenofovir-emtricitabine undergo different routes of elimination. Rilpivirine primarily undergoes oxidative metabolism through cytochrome P450 (CYP) 3A, while both tenofovir and emtricitabine are eliminated via a mixture of glomerular filtration and active tubular secretion.16,22,30,31 Both tenofovir and emtricitabine require dosage adjustment in patients with a creatinine clearance below 50 mL per minute while rilpivirine does not.16,21,25,37 Due to this disparity, fixed-dose combination rilpivirine-tenofovir-emtricitabine should not be administered to patients with a creatinine clearance below 50 mL per minute and the components should be separated to accommodate the necessary dosage adjustments. None of the components of this fixed-dose combination require dosage adjustment in patients with mild or moderate hepatic impairment.16 There are insufficient data about dosing and safety in patients with severe hepatic impairment.

Single-tablet regimens
Currently, there are two single-tablet regimen products that are commercially available, and the antiretroviral components are efavirenz-tenofovir-emtricitabine and rilpivirine-tenofovir-emtricitabine. Coformulation has significantly reduced the overall pill burden and improved the convenience of taking antiretroviral therapy. The majority of data regarding single-tablet regimens focus mainly on fixed-dose combination efavirenz-tenofovir-emtricitabine because it has been available since 2006. Nonetheless, the data available on fixed-dose combination efavirenz-tenofovir-emtricitabine are helpful in understanding the potential benefits of using a fixed-dose combination of rilpivirine-tenofovir-emtricitabine.

Several studies have demonstrated that switching to fixed-dose combination efavirenz-tenofovir-emtricitabine was generally effective in maintaining virologic suppression in patients who had an undetectable viral load at the time of switching therapy.38,39 The proportion of patients achieving virologic suppression was not significantly different among patients receiving fixed-dose combination efavirenz-tenofovir-emtricitabine compared with patients who received more complex antiretroviral regimens.39,40 These effects were seen out to 48 weeks in most studies and up to 96 weeks in one study.38 Given the potency of most antiretroviral agents, it is unsurprising that single-tablet regimen products achieve a similar frequency of virologic suppression compared with more complex antiretroviral regimens. Outcomes that may differentiate single-tablet regimen regimens from antiretroviral regimens with higher complexity include quality of life, adherence, patient preference, perceived medication regimen complexity, and tolerability.

In the ADONE study, health-related quality of life improved during the course of the study.38 Specifically, the difference in the quality of life measure was significantly improved after 24 weeks of switching to fixed-dose combination efavirenz-tenofovir-emtricitabine compared with baseline.38 Based on these data, single-tablet regimens appear to be beneficial for improving quality of life. However, when comparing the quality of life of single-tablet regimen recipients with that of patients who remained on their original antiretroviral
regimens, there may not be a meaningful change. In a trial of virologically suppressed HIV-infected patients randomized to either switch to fixed-dose combination efavirenz-tenofovir-emtricitabine or maintain their current antiretroviral regimen, quality of life measures did improve from baseline in either group. However, changes in these quality of life measures did not differ significantly between groups.

In the studies that have evaluated adherence, there appears to be a high proportion of patients adhering to single-tablet regimens through 48 weeks of therapy. There was also a higher preference for single-tablet regimens over original antiretroviral regimens, and patients perceived that single-tablet regimens were easier to follow than more complex treatment regimens. The tolerability of fixed-dose combination regimens will depend heavily on the components of the single-tablet regimen. The studies that have been performed thus far have been with fixed-dose combination efavirenz-tenofovir-emtricitabine, and the majority of adverse effects were related to efavirenz use. While the overall proportion of adverse events was low, there did appear to be a higher proportion of psychiatric symptoms, nervous system symptoms, and skin/tissue disorders among single-tablet regimen recipients compared with patients who did not modify their antiretroviral regimen. For the rilpivirine-containing single-tablet regimen, it is unclear if the frequency of adverse events will differ.

One interesting outcome of single-tablet regimen medication use is hospitalizations. Compared with patients using antiretroviral regimens that contain two or more pills per day, single-tablet regimen recipients were more likely to achieve optimal adherence thresholds and the risk of hospitalization was 25% lower. As more fixed-dose combination products emerge on the market, ancillary health outcomes, like hospitalizations, associated with single-tablet regimen use will need to be evaluated for each product. The majority of studies evaluating single-tablet regimen products have focused on populations that are either treatment-experienced or virologically suppressed and switching to a single-tablet regimen product. Outcomes for viremic patients who are initiating a single-tablet regimen product should be evaluated. Given that fixed-dose combination rilpivirine-tenofovir-emtricitabine is only approved for treatment-naïve individuals, the treatment outcomes of single-tablet regimens in treatment-naïve individuals will need to be assessed.

**Efficacy**

Rilpivirine has been evaluated in two Phase III studies, ie, ECHO (a Phase III randomized study of the efficacy of rilpivirine compared with efavirenz) and THRIVE (a randomized Phase III study of the efficacy of rilpivirine compared with efavirenz in HIV-infected patients using either tenofovir-emtricitabine, zidovudine-lamivudine, or abacavir-lamivudine). In the ECHO study, patients were exclusively prescribed tenofovir-emtricitabine as their nucleoside reverse transcriptase inhibitor backbone. In the THRIVE study, providers could choose between tenofovir-emtricitabine, lamivudine-zidovudine, or abacavir-lamivudine for the nucleoside reverse transcriptase inhibitor backbone. Sixty percent of patients in the THRIVE trial were given tenofovir-emtricitabine as their background nucleoside reverse transcriptase inhibitor regimen.

The ECHO trial was a randomized, double-blind, comparative study of rilpivirine versus efavirenz in treatment-naïve patients infected with HIV-1. The primary objective of the study was to show noninferiority between a rilpivirine-based and efavirenz-based antiretroviral regimen. The primary endpoint was the proportion of patients who achieved a viral load of <50 copies/mL or maintained a viral load <50 copies/mL after 48 weeks of treatment. Secondary endpoints included pharmacokinetics, safety, immune response, and emergence of drug resistance. Participants were individuals ≥18 years of age who were infected with HIV-1, were treatment-naïve, and had a baseline viral load >5000 copies/mL. Randomization was stratified by baseline viral load (≤100,000, ≤500,000, and >500,000 copies/mL).

After 1:1 randomization, the intention-to-treat analysis included 346 patients who were assigned to receive rilpivirine and 344 who received efavirenz-based therapy. At 48 weeks of treatment, 83% of patients in both groups had a confirmed virologic response, ie, a difference of 0.1% (95% confidence interval [CI] 0.1 [−5.5% to 5.7%]). Although the overall intention-to-treat outcomes were similar, the reasons for treatment failure differed between the treatment groups. More virologic failures for the efficacy endpoint (patients who never had virologic suppression or experienced virologic rebound) occurred with rilpivirine (38 patients [11%] with rilpivirine versus 15 patients [4%] with efavirenz). In contrast, more patients in the efavirenz group discontinued therapy and were considered a treatment failure due to adverse events. Specifically, 19 patients (7%) in the efavirenz group discontinued therapy due to an adverse event as compared with six patients (2%) in the rilpivirine group. The majority of adverse events leading to treatment discontinuation with
efavirenz were central nervous system effects. In a sensitivity analysis that excluded patients who discontinued therapy for reasons other than virologic failure, response rates were 86% (287/333) and 94% (285/303) for the rilpivirine and efavirenz groups, respectively (difference −7.9%, 95% CI −12.5% to −3.2%). The immunologic response was similar between the treatment groups, with a mean change in absolute CD4 count of 196 cells/µL (95% CI 179–212) for rilpivirine and 182 cells/µL (95% CI 165–198) for efavirenz (P = 0.13).

For the purpose of the 96-week analysis, data from the ECHO and THRIVE studies were pooled.41 Although the majority of patients in this pooled analysis used tenofovir-emtricitabine as their nucleoside reverse transcriptase inhibitor backbone regimen, there were patients using abacavir-lamivudine or zidovudine-lamivudine. The overall virologic response was 77.6% in both the rilpivirine and efavirenz treatment groups [95% CI (−4.4, 4.4)]. Immunologic response was also similar between groups and consistent with the 48-week ECHO data.

Again, although overall response rates were similar between groups, there were more virologic treatment failures in the rilpivirine group and more patients who discontinued therapy due to toxicity in the efavirenz group. For patients who entered the study with a baseline viral load >100,000 copies/mL, virologic failure was more common in the rilpivirine group. There was no difference in virologic failure shown for patients who entered the study with a baseline viral load ≤100,000 copies/mL.

**Safety**

Overall, the components of fixed-dose combination rilpivirine-tenofovir-emtricitabine demonstrate a favorable safety profile. The safety of rilpivirine has largely been judged based upon its comparison with efavirenz in clinical study.1,3 As highlighted in the efficacy section, overall adverse event rates were lower with rilpivirine, and significantly fewer patients discontinued rilpivirine therapy due to toxicity when compared with efavirenz. The main driver for these differences was central nervous system toxicity, a known and relatively common side effect of efavirenz.1,3 Although rilpivirine still has some risk for central nervous system toxicity (including headache, depressive disorders, and insomnia) it occurs significantly less often. Another important difference displayed in the ECHO and THRIVE studies was the difference in lipid effects between rilpivirine and efavirenz.1,3 Previous data show that efavirenz can cause significant increases in low-density lipoprotein, high-density lipoprotein, and total cholesterol.42–44 In clinical study, the effects of rilpivirine on the serum lipid profile were minimal. Grade 2 or higher changes in lipids and triglycerides occurred in less than 6% of rilpivirine-treated patients.1,3 Grade 2 lipid changes occurred in roughly 10%–20% of efavirenz-treated patients. Liver function tests were similar between rilpivirine and efavirenz treatment, with ≤3% of patients experiencing a grade 3 or 4 elevation in aspartate transaminase or alanine transaminase.1,3,44 Five percent of rilpivirine-treated patients experienced a grade 1 elevation in serum creatinine as compared with ≤1% with efavirenz-based therapy. The mean change was 0.09 mg/dL (range −0.20 mg/dL to 0.62 mg/dL). When increases in serum creatinine occurred, they most commonly occurred during the first month of therapy and persisted for the entire 48 weeks of therapy, and no subjects discontinued therapy due to increases in serum creatinine.41 The mechanism of this effect remains unknown and the clinical impact appears to be minimal according to the available data.

Other side effects observed with rilpivirine in clinical study include nausea and rash, both of which occurred in ≤3% of patients.1,2,41 Rilpivirine is associated with a dose-dependent increase in the QTc interval.25 At the approved dose of 25 mg, increases in the QTc interval appear to be minimal and are not expected to result in clinically adverse effects in patients without pre-existing cardiac conditions. At higher doses, the QTc prolongation effect is more pronounced and patients who are overdosed with rilpivirine should have electrocardiographic monitoring performed.25

The principal toxicity associated with use of tenofovir is nephrotoxicity.45 The most common form is proximal tubular toxicity characterized by electrolyte wasting and serum creatinine elevations. Fanconi syndrome and acute renal failure have been documented which, in some cases, have led to irreversible renal dysfunction.46–49 Clinical studies have shown the overall incidence of nephrotoxicity due to tenofovir to be <1%; however, small and gradual reductions in kidney function have more commonly been shown in clinical studies.50 Outside of the controlled setting of a clinical study, the true rates of tenofovir-induced nephrotoxicity appear to be higher. Numerous case reports and case series have been published to document this.46–48,51,52 Monitoring of renal function is recommended for patients who are prescribed a tenofovir-containing regimen. Particular attention should be paid to patients who have existing risk factors for tenofovir-induced nephrotoxicity. These risk factors include underlying renal dysfunction, older age, concurrent use of nephrotoxic medications, concurrent use of protease inhibitors, low body weight, and low CD4 count.53–56
Reductions in bone mineral density have also been documented in tenofovir-treated patients. Randomized clinical trials show that this effect occurs more commonly when patients are treated with tenofovir as compared with a regimen that does not contain tenofovir. As a result, it is recommended that consideration be given to assessing bone mineral density in tenofovir-treated patients with risk factors for osteoporosis or bone loss.

Emtricitabine has one of the strongest safety profiles when compared with other antiretroviral agents, and is generally considered to have minimal risk of toxicity. In clinical study, the most common adverse effects observed in antiretroviral regimens that included emtricitabine were headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, and rhinitis. However, it is important to note that it is difficult to discern whether these adverse effects were directly caused by emtricitabine or the coadministered antiretroviral agents. Hyperpigmentation and/or skin discoloration is a unique adverse effect that has been observed with emtricitabine but this effect occurs predominantly in children.

Safety data with the combination product, fixed-dose combination rilpivirine-tenofovir-emtricitabine are limited, although expected to be similar to what is observed when the individual agents are administered. As a result, mild adverse effects that may occur include gastrointestinal toxicities (nausea, vomiting, diarrhea), headache, and insomnia. More concerning adverse effects that require patient monitoring may include rash, renal dysfunction, loss of bone mineral density, and depressive disorders. To date, there are no toxicity data to suggest that adverse effect risks with fixed-dose combination rilpivirine-tenofovir-emtricitabine are different to those of the individual agents.

Resistance
Resistance associated with tenofovir and emtricitabine will not be discussed in this paper and are reviewed elsewhere. The resistance profile of rilpivirine is unique relative to other NNRTIs because it exhibits in vitro activity against both wild-type and drug-resistant HIV-1 isolates. Rilpivirine displays potent activity against HIV-1 strains that are resistant to older NNRTIs like efavirenz and nevirapine. At the present time, rilpivirine is only approved for use in patients that are treatment-naive. However, the activity of rilpivirine against HIV-1 isolates with diminished activity against first-generation NNRTIs may still be important to consider due to transmitted resistance risks. Approximately 5%–10% of treatment-naive patients acquire HIV infection with transmitted drug resistance and these patients experience a higher frequency of virologic failure when compared with patients who are transmitted drug-sensitive virus. As a result, rilpivirine may be an attractive option for treatment-naive patients with transmitted drug resistance to other NNRTIs.

In ECHO, there were some differences regarding virologic failure. Virologic failures with resistance occurred in 13% of patients in the rilpivirine treatment arm and 6% in the efavirenz group. There were 53 patients (40 in the rilpivirine group and 13 in the efavirenz group) who experienced virologic failure and had resistance data available at the time of failure. Among these patients, the frequency of virologic failure with any treatment-emergent NNRTI resistance-associated mutation was similar between rilpivirine and efavirenz groups (65% versus 62%, respectively). The most common treatment-emergent NNRTI resistance-associated mutation in the rilpivirine group was the E138K mutation (69%), followed by K101E (19%) and Y181C (19%). There was a significant difference in the proportion of patients who experienced virologic failure with any treatment-emergent International AIDS Society-USA (IAS-USA) nucleoside/nucleotide reverse transcriptase inhibitor resistance-associated mutation. Specifically, the frequency of M184I was 71% and 25% in rilpivirine and efavirenz patients, respectively.

In the THRIVE study, there appeared to be nearly a two-fold difference in the proportion of patients experiencing virologic failure with any treatment-emergent IAS-USA nucleoside/nucleotide reverse transcriptase inhibitor resistance-associated mutation (64% of rilpivirine patients compared with 33% of efavirenz patients). Among patients in the rilpivirine group experiencing virologic failure, the most common treatment-emergent NNRTI resistance-associated mutations were E138K (77%), K101E (73%), V189I (15%), and H221Y (15%). Among the IAS-USA nucleoside/nucleotide reverse transcriptase inhibitor resistance-associated mutations identified, the overall frequencies of the M184V and/or I mutations were 86% and 60% for patients in the rilpivirine and efavirenz groups, respectively, who experienced virologic failure.

A major resistance concern regarding antiretroviral resistance to NNRTI agents is the issue of cross-resistance. Patients who experienced virologic failure in the rilpivirine groups of the ECHO and THRIVE studies with evidence of phenotypic resistance to rilpivirine had evidence of cross-resistance to efavirenz, etravirine, and nevirapine. Specifically, of the
31 rilpivirine-treated patients who experienced virologic failure and developed phenotypic resistance to rilpivirine, the frequencies of cross-resistance to etravirine, efavirenz, and nevirapine were 90%, 87%, and 45%, respectively. Given that rilpivirine is a drug that is approved for treatment-naïve individuals, the issue of cross-resistance may deter its use in practice. Efavirenz, nevirapine, and etravirine have been used in patients who are treatment-experienced, and the antecedent use of rilpivirine in a treatment-naïve individual may limit the use of other NNRTI agents if virologic failure and phenotypic resistance occurs.

**Drug interactions**

Drug interactions with tenofovir and emtricitabine are described elsewhere. This review will focus on drug interactions associated with the rilpivirine component of fixed-dose combination rilpivirine-tenofovir-emtricitabine. Like most NNRTIs, rilpivirine is metabolized through the CYP isoenzyme system. It is both a substrate and inducer of CYP3A4. Rilpivirine is primarily metabolized by CYP 3A4. However, CYP2 C19, 1A2, and 2C8/9/10 are also involved. There are also some inductive effects associated with rilpivirine use. Specifically, rilpivirine is a moderate inducer of CYP 2C19 and 3A4 and has subtle induction effects on CYP 1A2 and 2B6. As a result of these effects on CYP isoenzymes and the necessity for an acidic gastric pH for absorption, there are a number of drug interactions associated with the use of the rilpivirine component of fixed-dose combination tenofovir-emtricitabine-rilpivirine. Select drug interactions with rilpivirine are represented in Table 3.

Drug interactions associated with rilpivirine use can be categorized as agents that should never be coadministered with rilpivirine, agents requiring adjustment or monitoring, and agents that require no intervention. An abbreviated list of drug interactions associated with rilpivirine use is found in Table 2. There are a number of agents that should not be coadministered with rilpivirine. The most notable are proton pump inhibitors, due to increases in gastric pH and reduction in rilpivirine concentrations. Additionally, anticonvulsants and antimycobacterials with CYP-inductive effects should be avoided with rilpivirine, because concentrations of rilpivirine may be decreased. Macrolide antibiotics like clarithromycin and erythromycin should be avoided due to CYP inhibition. Where possible, alternative macrolide agents like azithromycin should be utilized. Antacids and H2 receptor antagonists should be used with caution, and administration should be spaced out from rilpivirine administration. While there have not been studies evaluating this interaction, medications that prolong the QTc interval should be used with caution because there is a risk of QTc prolongation with rilpivirine at higher doses. It is unclear if the use of rilpivirine and a QTc prolonging medication would result in an accentuated risk of QTc prolongation. Electrocardiographic monitoring of high-risk patients using QTc prolonging medications and rilpivirine may be considered.

Of note, a significant interaction occurs when switching from efavirenz to rilpivirine. The long half-life of efavirenz may be concerning when switching to rilpivirine, because efavirenz concentrations persist for weeks after drug discontinuation and efavirenz induces the metabolism of rilpivirine. Pharmacokinetic differences were observed in a study of 20 healthy patients who received rilpivirine for 14 days followed by efavirenz for 14 days followed by a washout period and subsequently received efavirenz for 14 days followed by rilpivirine for 28 days. All rilpivirine pharmacokinetic exposures were significantly lower after efavirenz exposure compared with rilpivirine use prior to efavirenz exposure. A switch study was performed in HIV-infected patients with undetectable viral loads using efavirenz-tenofovir-emtricitabine who sought to switch to rilpivirine-tenofovir-emtricitabine due to intolerance. The average trough plasma rilpivirine concentration was 52 ng/mL two weeks after switching therapy. For weeks 4–12, the average trough plasma rilpivirine concentration was 66–84 ng/mL. In the clinical trials that evaluated the efficacy of rilpivirine, trough concentrations were 50–80 ng/mL. While the trough concentrations in the switch study did not fall below this range, it is unclear if patients may be at risk for subtherapeutic concentrations of rilpivirine in the presence of other medications that affect rilpivirine concentrations, like H2 receptor antagonists or antacids. Of note, the efavirenz

---

**Table 2** Pharmacokinetic characteristics

<table>
<thead>
<tr>
<th>Pharmacokinetic parameter</th>
<th>Rilpivirine</th>
<th>Tenofovir</th>
<th>Emtricitabine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral bioavailability</td>
<td>Unknown</td>
<td>25%</td>
<td>93%</td>
</tr>
<tr>
<td>Protein binding</td>
<td>99.7%</td>
<td>&lt;0.7%</td>
<td>&lt;4%</td>
</tr>
<tr>
<td>Elimination pathway</td>
<td>Hepatic</td>
<td>Renal</td>
<td>Renal</td>
</tr>
<tr>
<td>Elimination half-life</td>
<td>Approximately 48 hours</td>
<td>Approximately 17 hours</td>
<td>Approximately 10 hours</td>
</tr>
<tr>
<td>Predominant elimination pathway</td>
<td>Hepatic (CYP 3A)</td>
<td>Renal</td>
<td>Renal</td>
</tr>
</tbody>
</table>

*Abbreviation: CYP, cytochrome P450.*
Table 3 Abbreviated drug interactions associated with rilpivirine

<table>
<thead>
<tr>
<th>Concomitant medication</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medications that should not be coadministered with rilpivirine</strong></td>
<td></td>
</tr>
<tr>
<td>Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin</td>
<td>Strong CYP enzymatic induction may result in significant decreases in rilpivirine plasma concentrations.</td>
</tr>
<tr>
<td>Antimycobacterials: rifampin and rifabutin</td>
<td>Rilpivirine AUC, C_{\text{max}} and C_{\text{min}} decreased by 46%, 49%, and 35%, respectively, when used concomitantly with rifabutin. Rilpivirine AUC, C_{\text{max}} and C_{\text{min}} decreased by 80%, 89%, and 69%, respectively, when used concomitantly with rifampin.</td>
</tr>
<tr>
<td>Proton pump inhibitors</td>
<td>Changes in gastric pH leading to subsequent decreases in rilpivirine exposure. Rilpivirine AUC and C_{\text{min}} decrease by 40% and 33%, respectively, when omeprazole coadministered.</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>AUC of rilpivirine decreased by 70% in presence of efavirenz. Important pharmacokinetic implications when switching from efavirenz to rilpivirine. May extend to other NNRTI agents with persistent inductive effects on CYP system.</td>
</tr>
<tr>
<td>Macrolide antibiotics: clarithromycin, erythromycin</td>
<td>May result in increased exposure to rilpivirine through inhibition of CYP 3A. Consider use of azithromycin, where possible.</td>
</tr>
<tr>
<td><strong>Medications requiring adjustment or added monitoring when coadministered with rilpivirine</strong></td>
<td></td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Inhibition of CYP 3A isoenzymes may result in increased rilpivirine plasma concentrations (C_{\text{max}} and C_{\text{min}} increased by 30% and 76%, respectively) and decreased concentrations of ketoconazole (C_{\text{max}} and C_{\text{min}} decreased by 15% and 65%, respectively). Monitor for breakthrough fungal infections. Other antifungal agents may be evaluated for usage.</td>
</tr>
<tr>
<td>H2 receptor antagonists</td>
<td>Use with caution because H2 receptor antagonists increase the gastric pH. H2 receptor antagonists and rilpivirine should be spaced out. H2 receptor antagonists should be administered 12 hours before rilpivirine or 4 hours after rilpivirine ingestion.</td>
</tr>
<tr>
<td>Antacids</td>
<td>Antacids change gastric pH. Administer antacids 2 hours before or 4 hours after rilpivirine dose.</td>
</tr>
<tr>
<td>Methadone</td>
<td>AUC of R- and S-methadone decreased by 16% in the presence of rilpivirine. C_{\text{min}} of both R- and S-methadone decreased by about 21%. Monitor for signs of methadone withdrawal. May need to adjust dose.</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td>Potential for decreased concentrations of rilpivirine.</td>
</tr>
<tr>
<td>Medications known to prolong QT interval</td>
<td>Potential pharmacodynamic interaction with other QT prolonging medications.</td>
</tr>
<tr>
<td>Tenofovir</td>
<td>Rilpivirine pharmacokinetics virtually unchanged in presence of tenofovir. Tenofovir pharmacokinetics slightly elevated (C_{\text{min}} 24% higher) in presence of rilpivirine. Consider monitoring serum creatinine.</td>
</tr>
<tr>
<td><strong>Medications requiring no dosage adjustment or intervention</strong></td>
<td></td>
</tr>
<tr>
<td>Didanosine</td>
<td>Coadminister on an empty stomach.</td>
</tr>
<tr>
<td>Darunavir/ritonavir</td>
<td>No dosage adjustment recommended. However, rilpivirine AUC is 130% higher with darunavir/ritonavir coadministration.</td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>No dosage adjustment recommended. However, rilpivirine AUC is 52% higher with lopinavir/ritonavir coadministration.</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>No dosage adjustment recommended.</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>No dosage adjustment recommended.</td>
</tr>
<tr>
<td>Ethinyl estradiol</td>
<td>Subtle increases in AUC, C_{\text{max}} and C_{\text{min}} of ethinyl estradiol. No dosage adjustment necessary.</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>No dosage adjustment recommended.</td>
</tr>
</tbody>
</table>

**Abbreviations:** AUC, area under the concentration-time curve; C_{\text{max}}, peak plasma concentration; C_{\text{min}}, trough plasma concentration; CYP, cytochrome P450; NNRTI, non-nucleoside reverse transcriptase inhibitor.

concentrations remained above the IC₅₀ for 4 weeks after the switch to rilpivirine occurred.

**Place in therapy**

The vast majority of clinical data with fixed-dose combination rilpivirine-tenofovir-emtricitabine have emerged from studies performed in the treatment-naïve patient population. As a result, this is the patient population that will most commonly be prescribed fixed-dose combination rilpivirine-tenofovir-emtricitabine. To date, fixed-dose combination rilpivirine-tenofovir-emtricitabine has not been adequately studied in patients with existing antiretroviral drug resistance and is not officially indicated for use in treatment-experienced patients. Despite this, rilpivirine may remain a sensitive therapy option in patients who have developed resistance to first-generation NNRTI agents and future study...
may demonstrate a role for rilpivirine in this group. Patients with transmitted NNRTI resistance may be a particular target population for fixed-dose combination rilpivirine-tenofovir-emtricitabine.

The role of fixed-dose combination rilpivirine-tenofovir-emtricitabine has not been assessed in each antiretroviral treatment guideline to date. The United States Department of Health and Human Services antiretroviral treatment guidelines have recommended that fixed-dose combination rilpivirine-tenofovir-emtricitabine be considered as an alternative option for NNRTI-based therapy. Fixed-dose combination efavirenz-tenofovir-emtricitabine continues to be the preferred NNRTI for most patients, unless specific adverse event risks, such as pregnancy, preclude its use. Because patients who entered clinical study with a baseline viral load >100,000 copies/mL were more likely to experience virologic failure with rilpivirine-based therapy, caution is recommended when using fixed-dose combination rilpivirine-tenofovir-emtricitabine in patients with high viral loads (>100,000 copies/mL). Equally concerning is the higher rate of drug resistance exhibited after rilpivirine failure and the subsequent rate of phenotypic cross-resistance to etravirine, nevirapine, and efavirenz. Virologic failure and subsequent drug resistance with rilpivirine appears to limit future NNRTI therapy options more uniformly when compared with patients who experience virologic failure and drug resistance to other NNRTI agents.

When compared with the current standard of care, the advantage of rilpivirine in clinical study was its safety and tolerability. As a result, this is likely to be the greatest advantage of rilpivirine over existing therapy options, especially efavirenz. Given that efavirenz-based therapy continues to be the preferred NNRTI therapy option as per treatment guidelines, it is likely that fixed-dose combination rilpivirine-tenofovir-emtricitabine will fill an important need as transitional therapy in patients prescribed fixed-dose combination efavirenz-tenofovir-emtricitabine who are unable to tolerate adverse effects attributed to efavirenz. For example, if patients experience persistent central nervous system toxicity with fixed-dose combination efavirenz-tenofovir-emtricitabine, fixed-dose combination rilpivirine-tenofovir-emtricitabine is likely to represent an attractive therapy option, particularly when their HIV viral load is ≤100,000 copies/mL at the time of the switch. To date, there has been a small study to evaluate the safety and efficacy of switching patients from fixed-dose combination efavirenz-tenofovir-emtricitabine to fixed-dose combination rilpivirine-tenofovir-emtricitabine. Data from this study have demonstrated reliable efficacy and improved tolerability after the switch, but more data are necessary to ensure virologic efficacy after the switch, particularly when considering the pharmacokinetic drug interaction that occurs between efavirenz and rilpivirine within the first couple weeks after the switch. Another important advantage of fixed-dose combination rilpivirine-tenofovir-emtricitabine over fixed-dose combination efavirenz-tenofovir-emtricitabine is safety during pregnancy. Efavirenz is a pregnancy category D agent while rilpivirine is a pregnancy category B agent. When considering therapy for female patients of childbearing potential, fixed-dose combination rilpivirine-tenofovir-emtricitabine may be a preferred therapy option under certain circumstances.

Summary

Single-tablet regimens represent an enormous step forward in the objective of providing safe, effective, and conveniently dosed antiretroviral therapy to HIV-infected patients. Fixed-dose combination rilpivirine-tenofovir-emtricitabine has been shown to provide a high degree of virologic efficacy and safety in clinical study and will be an important therapy option for some patients. When compared with the current standard of care, concerns over increased risk for virologic failure and drug resistance, particularly among patients with high viral loads, will limit its widespread use in the HIV population. Due to the unique resistance profile of rilpivirine relative to first-generation NNRTI agents, fixed-dose combination rilpivirine-tenofovir-emtricitabine may prove to have an important therapeutic role for patients with existing antiretroviral resistance, but clinical studies are currently lacking in this patient population. For now, the most likely role for fixed-dose combination rilpivirine-tenofovir-emtricitabine is to provide an important role as a switch therapy for patients experiencing adverse effects on the current NNRTI standard of care.

Disclosure

CDM is on the speakers bureau for Bristol Myers Squibb. The authors otherwise report no conflicts of interest in this work.

References


